IKZF1 Δ2-8/ALB gene deletions and clinical features
The patients were divided into two groups: IKZF1 Δ2-8/ALB deletions of < 1% (Group A) and of ≥ 1% (Group B). The rates of age at onset of ≥ 10 years old, white blood cell count (WBC) of ≥ 50×109/L at initial diagnosis, and HR patients in Group B, were significantly higher than in Group A (P < 0.05). Patients who were positive for the ETV6/RUNX1 fusion gene in Group A accounted for 17.8%, which was higher than in Group B. However, the level of IKZF1 deletions was not associated with sex, WBC counts, lactate dehydrogenase (LDH), uricacid (UA), immunologic subtype, or karyotype. The central nervous system leukemia (CNSL) rate between the two groups were similar. More patients were treated with TKIs and underwent HSCT in Group B than in Group A (P < 0.05). The characteristics of patients with BCP-ALL with different IKZF1 Δ2-8/ALB deletion levels are summarized in Table 1.